Shares of Eli Lilly & Co. LLY rose 1.07% to $773.29 Tuesday, on what proved to be an all-around grim trading session for the ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.